Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma. [electronic resource]
Producer: 20151201Description: 331-40 p. digitalISSN:- 1744-8379
- Acetylmuramyl-Alanyl-Isoglutamine -- administration & dosage
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bone Neoplasms -- drug therapy
- Child
- Child, Preschool
- Clinical Trials, Phase III as Topic
- Cost-Benefit Analysis
- Female
- Humans
- Infant
- Male
- Markov Chains
- Orphan Drug Production -- economics
- Osteosarcoma -- drug therapy
- Phosphatidylethanolamines -- administration & dosage
- Quality-Adjusted Life Years
- Spain
- Young Adult
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.